Chidozie Ugwumba Sells 73,296 Shares of Clene (NASDAQ:CLNN) Stock

Posted by Kyle Jackson on May 15th, 2026

Clene Inc. (NASDAQ:CLNN – Get Free Report) major shareholder Chidozie Ugwumba sold 73,296 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $6.20, for a total transaction of $454,435.20. Following the completion of the transaction, the insider owned 103,417 shares of the company’s stock, valued at approximately $641,185.40. The trade was a 41.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

On Monday, May 11th, Chidozie Ugwumba sold 22,177 shares of Clene stock. The stock was sold at an average price of $6.75, for a total transaction of $149,694.75.
On Monday, May 4th, Chidozie Ugwumba sold 72,884 shares of Clene stock. The stock was sold at an average price of $6.80, for a total transaction of $495,611.20.
On Friday, May 1st, Chidozie Ugwumba sold 5,795 shares of Clene stock. The stock was sold at an average price of $6.01, for a total transaction of $34,827.95.
On Thursday, April 30th, Chidozie Ugwumba sold 5,736 shares of Clene stock. The stock was sold at an average price of $6.08, for a total transaction of $34,874.88.
On Wednesday, April 29th, Chidozie Ugwumba sold 12,170 shares of Clene stock. The stock was sold at an average price of $5.63, for a total transaction of $68,517.10.
On Tuesday, April 28th, Chidozie Ugwumba sold 1,591 shares of Clene stock. The stock was sold at an average price of $5.90, for a total transaction of $9,386.90.
On Tuesday, April 21st, Chidozie Ugwumba sold 61,345 shares of Clene stock. The stock was sold at an average price of $6.14, for a total transaction of $376,658.30.
On Monday, April 20th, Chidozie Ugwumba sold 4,318 shares of Clene stock. The stock was sold at an average price of $6.12, for a total transaction of $26,426.16.
On Friday, April 17th, Chidozie Ugwumba sold 25,040 shares of Clene stock. The stock was sold at an average price of $6.43, for a total transaction of $161,007.20.
On Thursday, April 16th, Chidozie Ugwumba sold 7,748 shares of Clene stock. The shares were sold at an average price of $6.40, for a total transaction of $49,587.20.

Clene Stock Performance

NASDAQ:CLNN opened at $7.05 on Friday. The firm has a market cap of $83.03 million, a P/E ratio of -2.71 and a beta of 0.89. Clene Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $13.50. The firm has a 50-day simple moving average of $5.98 and a two-hundred day simple moving average of $6.39.

Clene (NASDAQ:CLNN – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.05). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. On average, equities research analysts predict that Clene Inc. will post -1.99 EPS for the current year.

Analyst Upgrades and Downgrades

CLNN has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. HC Wainwright restated a “buy” rating and set a $31.00 price objective on shares of Clene in a research note on Monday, May 4th. Canaccord Genuity Group restated a “buy” rating and set a $48.00 price objective on shares of Clene in a research note on Friday, March 13th. Roth Mkm restated a “buy” rating on shares of Clene in a research note on Thursday. Finally, D. Boral Capital restated a “buy” rating and set a $23.00 price objective on shares of Clene in a research note on Monday, May 4th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Clene presently has an average rating of “Moderate Buy” and an average target price of $33.25.

Read Our Latest Stock Report on CLNN

Institutional Trading of Clene

A number of institutional investors have recently made changes to their positions in the stock. Lunt Capital Management Inc. boosted its holdings in shares of Clene by 2.5% during the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after acquiring an additional 1,250 shares during the last quarter. Jones Financial Companies Lllp purchased a new position in shares of Clene in the third quarter worth approximately $29,000. Geode Capital Management LLC boosted its holdings in shares of Clene by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock worth $482,000 after buying an additional 6,090 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Clene in the second quarter worth approximately $47,000. Finally, State Street Corp boosted its holdings in shares of Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after buying an additional 17,300 shares during the last quarter. Hedge funds and other institutional investors own 23.28% of the company’s stock.

About Clene

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).